knowledge -WSS

knowledge

author：fashion 2025-09-30 17:45:45 - browse：6628

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： How to bring more disabled researchers into academia

https://cbu01.alicdn.com/img/ibank/2015/448/156/2330651844_715837672.220x220xz.jpg

focus

leisure time

WSS

Headspace, Meta partner to launch VR meditation app for Quest

CDC marks new Covid

FogPharma raises $145 million in rare Series E round

CDC marks new Covid

Novo Nordisk obesity pill bests Wegovy in early trial

ALS groups 'won't be played again' by the FDA, drug sponsors

entertainment

knowledge

explore

23andMe had bad news about my health. I wish a person had delivered it

Medical device lobby: We're tired of waiting on Medicare coverage

DIEP, the 'gold standard' of breast reconstruction, is under threat

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

United colonoscopy coverage change 'may cost lives,' doctors say

What it’s like to watch children die of measles

New air purifier tech could be key to improving indoor air quality

First medicine developed to treat MASH expected to be approved soon

Trump demands the U.S. pay no more for drugs than other countries … again

In search for therapies for solid tumors, companies turn to claudin

focus

The problem with charging patients to message their doctors

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Headspace, Meta partner to launch VR meditation app for Quest

IVF, abortion rights issues kick off Biden’s State of the Union

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

https://cbu01.alicdn.com/img/ibank/2015/448/156/2330651844_715837672.220x220xz.jpg

focus

leisure time

focus